Literature DB >> 10627427

Impaired microvascular response to cholinergic stimuli in primary Sjögren's syndrome.

L Kovács1, T Török, F Bari, Z Kéri, A Kovács, E Makula, G Pokorny.   

Abstract

OBJECTIVE: Signs of a parasympathetic dysfunction have been revealed in primary Sjögren's syndrome (SS). Its role in the pathogenesis and the clinical picture of the disease is not clear. To investigate the responsiveness of SS patients to a cholinergic agonist, a model was used involving examination of the cutaneous microcirculation. The microvascular response to the administration of carbachol was measured, a muscarinic cholinergic agonist.
METHODS: Twenty two SS patients and 12 controls were examined. Carbachol and 0.9% saline solution were administered intracutaneously into the forearm skin at two distinct places. Skin blood flow (SBF) in the injected areas was measured continuously before and for 10 minutes after the injections by means of a laser Doppler perfusion monitor. The increase in SBF in response to carbachol (dSBF), reflecting vasodilatation, was calculated by a formula including the baseline and the maximum SBF values after the injections of carbachol and saline solution.
RESULTS: The vasodilatation was significantly lower in SS patients than in the controls (mean dSBF: 2.1 (range: 1.0-4.5) versus 3.3 (range: 1.7-7.6), p=0.02). With non-responder patients defined as those in whom a smaller response was observed than in any of the controls, 11 of the 22 SS patients proved to be non-responders to carbachol. Comparisons of demographic, clinical and laboratory characteristics and HLA class II genotypes between responder and non-responder SS patients did not show any significant differences.
CONCLUSIONS: A diminished or absent response to carbachol indicates a cholinergic dysfunction in SS patients. A disturbance in the neurotransmission at a receptorial or postreceptorial level is hypothesised. Unresponsiveness to cholinergic stimuli may contribute to exocrine insufficiency.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10627427      PMCID: PMC1752981          DOI: 10.1136/ard.59.1.48

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  Autonomic cardiovascular neuropathy in Sjögren's syndrome. A controlled study.

Authors:  A P Andonopoulos; J Christodoulou; C Ballas; A Bounas; D Alexopoulos
Journal:  J Rheumatol       Date:  1998-12       Impact factor: 4.666

2.  Disturbances of autonomic nervous function in primary Sjögren's syndrome.

Authors:  T Mandl; L Jacobsson; B Lilja; G Sundkvist; R Manthorpe
Journal:  Scand J Rheumatol       Date:  1997       Impact factor: 3.641

3.  Protein kinase C expression in salivary gland acinar epithelial cells in Sjögren's syndrome.

Authors:  J Törnwall; Y T Konttinen; R K Tuominen; M Törnwall
Journal:  Lancet       Date:  1997-06-21       Impact factor: 79.321

Review 4.  Pathogenesis and treatment of Sjögren's syndrome.

Authors:  R I Fox; T Maruyama
Journal:  Curr Opin Rheumatol       Date:  1997-09       Impact factor: 5.006

5.  Modified PCR-RFLP method for HLA-DPB1 and -DQA1 genotyping.

Authors:  M Ota; T Seki; N Nomura; K Sugimura; N Mizuki; H Fukushima; K Tsuji; H Inoko
Journal:  Tissue Antigens       Date:  1991-08

6.  Neuropeptides of the autonomic nervous system in Sjögren's syndrome.

Authors:  N Santavirta; Y T Konttinen; J Törnwall; M Segerberg; S Santavirta; M Matucci-Cerinic; H Björvell
Journal:  Ann Rheum Dis       Date:  1997-12       Impact factor: 19.103

7.  Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome.

Authors:  S Bacman; L Sterin-Borda; J J Camusso; R Arana; O Hubscher; E Borda
Journal:  Clin Exp Immunol       Date:  1996-06       Impact factor: 4.330

Review 8.  The etiopathogenesis of Sjögren's syndrome.

Authors:  E J Price; P J Venables
Journal:  Semin Arthritis Rheum       Date:  1995-10       Impact factor: 5.532

9.  Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission.

Authors:  D L Kellogg; P E Pérgola; K L Piest; W A Kosiba; C G Crandall; M Grossmann; J M Johnson
Journal:  Circ Res       Date:  1995-12       Impact factor: 17.367

10.  Carbachol, substance P, and phorbol ester promote the tyrosine phosphorylation of protein kinase C delta in salivary gland epithelial cells.

Authors:  S P Soltoff; A Toker
Journal:  J Biol Chem       Date:  1995-06-02       Impact factor: 5.157

View more
  7 in total

Review 1.  Central nervous system mechanisms in Sjögren's syndrome.

Authors:  O P van Bijsterveld; A A Kruize; R L A W Bleys
Journal:  Br J Ophthalmol       Date:  2003-02       Impact factor: 4.638

2.  cAMP-dependent recruitment of acidic organelles for Ca2+ signaling in the salivary gland.

Authors:  John F Imbery; Sumit Bhattacharya; Sura Khuder; Amanda Weiss; Priyodarshan Goswamee; Azwar K Iqbal; David R Giovannucci
Journal:  Am J Physiol Cell Physiol       Date:  2016-09-07       Impact factor: 4.249

Review 3.  Sjögren's syndrome--study of autoantigens and autoantibodies.

Authors:  John G Routsias; Athanasios G Tzioufas
Journal:  Clin Rev Allergy Immunol       Date:  2007-06       Impact factor: 8.667

Review 4.  Parasympathetic nervous system dysfunction in primary Sjögren's syndrome.

Authors:  A Hocevar; M Tomsic; S Praprotnik; M Hojnik; T Kveder; B Rozman
Journal:  Ann Rheum Dis       Date:  2003-08       Impact factor: 19.103

Review 5.  Dysfunction of lacrimal and salivary glands in Sjögren's syndrome: nonimmunologic injury in preinflammatory phase and mouse model.

Authors:  Toshiharu Hayashi
Journal:  J Biomed Biotechnol       Date:  2011-06-01

Review 6.  Autonomic Nervous System Dysfunction in Primary Sjögren's Syndrome.

Authors:  Kristen Davies; Wan-Fai Ng
Journal:  Front Immunol       Date:  2021-07-26       Impact factor: 7.561

7.  Mild autonomic dysfunction in primary Sjögren's syndrome: a controlled study.

Authors:  Fin Z J Cai; Sue Lester; Tim Lu; Helen Keen; Karyn Boundy; Susanna M Proudman; Anne Tonkin; Maureen Rischmueller
Journal:  Arthritis Res Ther       Date:  2008-03-07       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.